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Summary 
I 
Summary 
Endothelial cells (ECs) function as protective barrier to separate the blood from the surrounding 
tissue by conducting crucial roles in regulation and maintenance of vascular homeostasis, such as 
control of vessel permeability or coagulation. Therefore, dysfunction of the EC barrier due to 
inflammation, infection or injury can cause a variety of vascular pathologies, such as thrombosis 
or atherosclerosis. In this context, the circulating extracellular endonuclease Ribonuclease 1 
(RNase1) was identified as a vessel- and tissue-protective enzyme and a potent regulator of 
vascular homeostasis. Upon acute inflammation, RNase1 functions as a natural counterpart to 
extracellular RNA (eRNA), a damage-associated molecular pattern, via degradation to protect the 
EC cell layer from excessive inflammation. However, long-term inflammation disrupts the 
RNase1-eRNA system. Thereby, eRNA accumulates in the extracellular space to induce massive 
proinflammatory cytokine release from circulating inflammatory cells, such as tumor necrosis 
factor alpha (TNF-α) or interleukin 1 beta (IL-1β). These cytokines negatively affect the EC layer 
by downregulation of RNase1 presumably through activation of histone deacetylases (HDACs). 
In this regard, this study investigated whether inflammation-mediated deacetylase function of 
HDACs suppresses RNase1 expression in human ECs through modulation of chromatin 
modifications. Proinflammatory stimulation with TNF-α or IL-1β of human umbilical vein 
endothelial cells significantly reduced RNase1 expression. Thus, identification of the RNASE1 
promoter region and analysis of its chromatin state revealed the association of RNASE1 repression 
with deacetylation of histone 3 at lysine 27 and histone 4. The important role of HDACs in this 
process was further confirmed by administration of the specific class I HDAC1-3 inhibitor 
MS275 that successfully restored RNASE1 promoter acetylation and mRNA abundance upon 
TNF-α or IL-1β treatment. These results indicate an essential impact of HDAC1-3 in RNase1 
regulation. Additionally, identification of specific HDACs involved in RNase1 regulation was 
obtained by chromatin immunoprecipitation kinetics confirming significant accumulation of 
HDAC2 at the RNASE1 promoter upon TNF-α stimulation. These findings were further validated 
by siRNA double knockdown of HDAC2 and its redundant enzyme HDAC1, which also 
recovered RNase1 mRNA abundance upon proinflammatory stimulation. In conclusion, our data 
identified HDAC2 as a crucial factor in RNase1 regulation in human ECs. HDAC2 is recruited to 
the RNASE1 promoter site to attenuate histone acetylation and suppress subsequent gene 
repression. This effect can be blocked by the specific HDAC inhibitor MS275 implicating the 
potential of HDAC inhibitors as novel therapeutic strategy to promote vascular integrity by 
preventing RNase1 downregulation in EC inflammation.
Zusammenfassung 
II 
Zusammenfassung 
Endothelzellen fungieren als schützende Barriere zwischen Blut und Gewebe und sind 
maßgeblich an der Regulation und Aufrechterhaltung der vaskulären Homöostase beteiligt. 
Demzufolge kann eine Fehlfunktion des Endothels auf Grund von Entzündungen, Infektionen 
oder Verletzungen zu einer Vielzahl von Krankheitszuständen, wie Thrombosen oder 
Atherosklerose, führen. In diesem Kontext wurde Ribonuklease 1 (RNase1), eine zirkulierende, 
extrazelluläre Endonuklease, als gefäß- und gewebeschützendes Enzym und wichtiger Regulator 
der vaskulären Homöostase identifiziert. Bei akuten Entzündungsprozessen fungiert RNase1 als 
natürlicher Gegenspieler der extrazellulären RNA (eRNA), einem „damage-associated molecular 
pattern“. Hierbei degradiert RNase1 akkumulierende eRNA, um die Zellen vor einer über-
mäßigen Entzündungsreaktion zu schützen. Bei lang anhaltenden Entzündungen kommt es jedoch 
zu einer Störung des RNase1-eRNA Gleichgewichtes. Dabei induziert die Akkumulation von 
eRNA die Freisetzung großer Mengen proinflammatorischer Zytokine durch zirkulierende 
Entzündungszellen, wie zum Beispiel Tumornekrosefaktor alpha (TNF-α) oder Interleukin 1 beta 
(IL-1β). Diese Zytokine können das Endothel entzündungsbedingt beeinflussen und führen unter 
Anderem zur Repression der RNase1-Expression, welche möglicherweise durch die Aktivierung 
von Histon-Deacetylasen (HDACs) vermittelt wird. Die hier vorliegende Studie untersuchte, ob 
die entzündungsvermittelte Deacetylasefunktion der HDACs durch Veränderung von 
Chromatinmodifikationen mit der RNase1-Repression in humanen Endothelzellen einhergeht. 
Dabei führte die Stimulation humaner Nabelschnurvenenendothelzellen mit TNF-α oder IL-1β zu 
einer signifikanten Reduktion der RNase1-Expression. Durch Identifizierung der RNASE1-
Promotorregion und Analysen des Chromatinstatus wurde weiterhin eine Verbindung zwischen 
der RNase1-Repression und der Deacetylierung von Histon 3 Lysin 27 und Histon 4 aufgezeigt. 
Zusätzlich konnte durch Inhibierung der Klasse I-HDACs 1-3, mittels des spezifischen Inhibitors 
MS275, die RNase1 mRNA sowie die damit verbundene Promotoracetylierung selbst nach 
Zytokinstimulation der Endothelzellen wiederhergestellt werden. Zur Identifizierung der 
funktionellen HDAC wurden Chromatin-Immunopräzipitations-Kinetiken durchgeführt, welche 
eine signifikante Akkumulation von HDAC2 am RNASE1-Promotor nach TNF-α-Stimulation 
aufzeigten. Diese Ergebnisse wurden durch siRNA-vermittelte Hemmung der HDAC2-
Expression und dessen redundanten Enzyms HDAC1 bestätigt, da auch diese Behandlung die 
RNase1 mRNA-Expression nach proinflammatorischer Stimulation wiederherstellen konnte. 
Diese Ergebnisse identifizieren HDAC2 als einen Hauptfaktor in der RNase1-Regulation in 
humanen Endothelzellen. Dabei wird HDAC2 nach proinflammatorischer Stimulation zum 
RNASE1-Promotor rekrutiert, um die Histonacetylierung zu verhindern und so die Genexpression 
zu reprimieren. Demzufolge eröffnet der hier aufgezeigte protektive Effekt des spezifischen 
HDAC-Inhibitors MS275 neuartige Therapieansätze zur Förderung der Gefäßintegrität durch 
Verhinderung der RNase1-Repression in entzündeten Endothelzellen. 
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1 Introduction 
 Inflammation of endothelial cells 
The endothelial cell (EC) layer forms the inner lining of all blood vessels and functions as physical 
barrier to separate the blood from the surrounding tissue. Thereby, ECs conduct multiple 
functions in regulating maintenance and integrity of vascular homeostasis, such as control of 
vessel permeability, blood fluidity, or coagulation and platelet function (Pober and Sessa, 2007; 
Rajendran et al., 2013). Under physiological conditions, resting ECs avoid interaction with 
circulating leukocytes. Thereby, they sequester leukocyte interactive proteins, like adhesion 
molecules or chemokines, within their secretory vesicles called Weibel-Palade Bodies (WPBs) 
(Pober and Sessa, 2007; Rondaij et al., 2006), and suppress transcription of membrane bound 
adhesion molecules, (e.g. endothelial selectin (E-selectin), intracellular adhesion molecule 
(ICAM)-1) or proinflammatory cytokines to prevent leukocyte interaction (De Caterina et al., 
1995; Pober and Sessa, 2007). Upon inflammation, ECs get rapidly activated to support the 
recruitment, attachment and interaction with leukocytes, for instance via initiation of WPB 
exocytosis and activation of proinflammatory gene expression to release leukocyte attractant 
chemokines and transport adhesion molecules to the EC surface. Consequently, leukocytes 
interact with the EC layer to leave the vessel and infiltrate the tissue, thereby secreting further 
proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-α) or interleukin (IL)-1β 
(Pober and Sessa, 2007). Due to this inflammation, the homeostatic function of the EC layer may 
be affected resulting in dysfunction of the endothelium, which favors progression of vascular 
diseases, such as atherosclerosis, thrombosis or myocardial infarction (Poredos, 2002; Sitia et al., 
2010; Zernecke and Preissner, 2016). In this regard, cardiovascular pathologies depict one of the 
main causes of death worldwide with several million fatalities per year according to the World 
Health Organization (WHO) (WHO, 2017). 
 RNase1 function in endothelial cells 
Previous research concerning cardiovascular pathologies, such as atherosclerosis or thrombosis, 
described the important function of a novel protective factor during EC inflammation called 
Ribonuclease (RNase1) (Cabrera-Fuentes et al., 2014; Fischer et al., 2007; Kannemeier et al., 
2007; Simsekyilmaz et al., 2014; Zernecke and Preissner, 2016). RNase1 is one of eight secretable 
members of the mammalian ribonuclease A (RNaseA) superfamily that possesses ribonuclease 
activity (Koczera et al., 2016; Sorrentino, 2010). The biological relevance of the RNaseA 
superfamily varies from host defense to angiogenesis and digestion. However, the precise 
physiological functions of RNases need to be further investigated (Koczera et al., 2016). RNase1, 
also known as RNaseA or pancreatic-type RNase, is produced in various tissues, e.g. pancreas, 
testis, ovary or brain (Futami et al., 1997; Koczera et al., 2016; Landre et al., 2002; Moenner et 
al., 1997), and was shown to be predominantly expressed by vascular ECs where it is stored and 
released from WBPs (Fischer et al., 2011; Futami et al., 1997; Landre et al., 2002; Lu et al., 
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2018). Additionally, previous studies indicated that especially human umbilical vein endothelial 
cells (HUVEC) express and secrete high amounts of active RNase1 (Fischer et al., 2011; Landre 
et al., 2002), offering an ideal model system to study RNase1 function and regulation. Due to the 
high secretory levels of RNase1, a non-digestive function of this enzyme was suggested in 
humans and its endothelial origin pointed towards a regulatory role in maintenance of vascular 
homeostasis (Fischer et al., 2007; Kannemeier et al., 2007; Landre et al., 2002; Sorrentino et al., 
2003).  
RNase1 function in acute and long-term EC inflammation 
The predicted role of RNase1 in regulation and maintenance of vascular homeostasis was further 
confirmed by Gansler et al. who firstly described a regulatory mechanism for RNase1 in inflamed 
endothelial cells, thereby revealing its importance as regulatory factor for maintenance and 
integrity of vascular homeostasis (Gansler et al., 2014). In acute inflammation (Figure IA)1, ECs 
release leukocyte interactive proteins and chemokines as well as a subset of damage-associated 
molecular patterns, such as extracellular RNA (eRNA). Thereby, the danger-associated signal 
eRNA is released to the extracellular space to induce the immune response2 (Fischer et al., 2013; 
Fischer et al., 2012; Gansler et al., 2014; Zernecke and Preissner, 2016), and further mediate 
degranulation of WPBs3 from ECs resulting in release of proinflammatory agents and RNase14. 
Once released, RNase1 acts as a natural counterpart to eRNA via degradation5 to protect the EC 
layer from eRNA-mediated overwhelming inflammatory responses (Cabrera-Fuentes et al., 
2015b; Cabrera-Fuentes et al., 2014; Gansler et al., 2014). However, upon long-term 
inflammation, the balance of the RNase1-eRNA system gets disturbed (Figure IB). Prolonged 
inflammation of ECs results in accumulation of eRNA in the extracellular space, which promotes 
recruitment of inflammatory cells, such as monocytes, to the site of inflammation1 (Cabrera-
Fuentes et al., 2015a; Fischer et al., 2013; Gansler et al., 2014). These inflammatory cells release 
high amounts of proinflammatory cytokines, like TNF-α and IL-1β2, which further contribute to 
a disturbed EC barrier function by increasing vascular permeability through redistribution of 
adhesion molecules3 as well as massive downregulation of RNase14 (Gansler et al., 2014). 
Consequently, RNase1 protein translation, its storage and release from WPBs5 as well as its 
function in eRNA degradation is impaired resulting in subsequent eRNA accumulation and EC 
dysfunction6 (Gansler et al., 2014).   
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Figure I: RNase1 function in acute and long-term endothelial cell inflammation. Schematic illustration 
of RNase1 function in inflamed endothelial cells (ECs). A) eRNA release upon acute inflammation of ECs 
mediates degranulation of Weibel-Palade Bodies to release RNase1 and proinflammatory agents to protect 
vascular homeostasis. B) Upon long-term inflammation, eRNA accumulation promotes proinflammatory 
cytokine secretion of recruited monocytes that further affect EC function by redistribution of adhesion 
molecules and downregulation of RNase1 to block eRNA degradation. Abbreviations: eRNA, extracellular 
RNA; IL-1β, interleukin 1 beta; RNase1, Ribonuclease1; TNF-α, tumor necrosis factor alpha. 
 Chromatin structure and dynamics 
Compaction of the human genome is a necessity in order to pack the large amount of DNA into 
a single nucleus and to ensure the precise function of all regulatory processes in the cell, such as 
DNA replication, repair or transcription (Luger et al., 2012). Thereby, the DNA passes through 
different stages of compaction, starting with the DNA double helix, through chromatin and 
chromatin fibers of packed nucleosomes, to sections of extended and condensed chromosomes, 
ending up with the entire mitotic chromosome structure (Figure IIA) (Fyodorov et al., 2018). A 
particularly important packaging level is the so called “beads on a string” structure of chromatin, 
where the DNA is coiled on beads to form the nucleosomes, the basic repeat units of the 
chromatin. Each nucleosome core particle consists of approximately 146 base pairs (bp) of DNA, 
which are wrapped around an octameric core of histone (H) proteins (Luger et al., 2012; Luger et 
al., 1997). There exist five histone proteins, H1, H2A, H2B, H3 and H4, that built up the octameric 
nucleosome core by two H2A-H2B dimers and one H3-H4 tetramer, while the linker histone H1 
together with the linker DNA connects the individual nucleosomes to form higher organizational 
units of DNA (Jenuwein and Allis, 2001; Luger et al., 2012; Luger et al., 1997). These small, 
highly conserved, basic proteins contain positively charged N-terminal tails that are highly 
subjected to post-translational modifications (PTMs), such as phosphorylation of serine residues, 
methylation of arginine residues or acetylation of lysine residues (Kouzarides, 2007). Thereby, 
PTMs of the core histones are decisive for regulation of the chromatin structure and function and 
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adjust several DNA-related processes, such as transcription or replication (Bannister and 
Kouzarides, 2011; Fyodorov et al., 2018; Grewal and Elgin, 2007; Portela and Esteller, 2010). 
HATs and HDACs as modulators of histone acetylation 
One of the first identified histone modifications, discovered by Allfrey et al. in 1964, was the 
acetylation (ac) of lysine residues (Allfrey et al., 1964; Gershey et al., 1968), which acts as critical 
regulator of gene expression (Durrin et al., 1991; Megee et al., 1990; Roh et al., 2005). 
Acetylations thus function as specific markers for active and transcribed chromatin, such as 
histone 4 acetylation (H4ac) and histone 3 lysine 27 acetylation (H3K27ac) (Kouzarides, 2007; 
Wang et al., 2008). The enzymes that modulate the pattern of histone acetylation are histone 
acetyl transferases (HATs) and histone deacetylases (HDACs) (Figure IIB). Due to their 
enzymatic function, HATs and HDACs facilitate the addition or removal of acetyl groups on 
lysine residues of N-terminal histone tails to modulate the intensity of histone-DNA interactions 
(Bannister and Kouzarides, 2011; Fyodorov et al., 2018; Grewal and Elgin, 2007). HATs transfer 
acetyl groups to lysine residues to decrease the positive histone charge and weaken the interaction 
of histones with the negatively charged DNA. Thereby, providing access for the transcriptional 
machinery to the DNA by opening the densely packed chromatin structure (Zentner and Henikoff, 
2013). Vice versa, deacetylation of lysine residues is catalyzed through HDACs to amplify the 
histone-DNA interaction by enhancing the positive histone charge. This provokes strong 
histone-DNA interactions and a tightly packed, inactive chromatin structure, which ultimately 
leads to transcriptional repression (Grewal and Elgin, 2007; Seto and Yoshida, 2014).  
 
Figure II: Chromatin structure and dynamics. Schematic illustration of A) DNA packaging and B) 
chromatin remodeling by histone acetylation. A) Different stages of DNA compaction to mediate packaging 
of a large amount of DNA into the nucleus of a cell. B) Histone acetylation on lysine residues of N-terminal 
histone tails is mediated by HATs to promote an open chromatin structure and gene expression. Vice versa, 
histone deacetylation is mediated by HDACs to promote a condensed chromatin structure and 
transcriptional repression. Abbreviations: Ac, acetylation; DNA, deoxyribonucleic acid; HAT, histone 
acetyl transferase; HDAC, histone deacetylase.  
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Histone deacetylases as erasers of histone acetylation 
HDAC enzymes were firstly described in 1969 (Inoue and Fujimoto, 1969), however, it took 
several decades until the first enzyme, HDAC1, was isolated by Taunton and colleagues and 
identified as orthologue of yeast Rpd3 protein (Taunton et al., 1996). The family of histone 
deacetylases consists of so far 18 members, divided into 4 distinct classes of enzymes that are 
distinguished based on their sequence similarity (de Ruijter et al., 2003; Micelli and Rastelli, 
2015): Class I enzymes, HDAC1, HDAC2, HDAC3 and HDAC8, share sequence homology with 
the yeast Rpd3 protein, while class II enzymes, including class IIa (HDAC4, HDAC5, HDAC7 
and HDAC9) and class IIb (HDAC6 and HDAC10), share sequence similarity with yeast Hda1 
protein. Compared to that, the class III HDAC proteins SIRT1-7 belong to the conserved family 
of sirtuins (Sir2 deacetylases), sharing homology with yeast Sir2, while class IV consists of only 
one enzyme, HDAC11, with limited overall sequence identity to other HDAC classes (Micelli 
and Rastelli, 2015; Seto and Yoshida, 2014; Yang and Seto, 2008). Besides their important 
function in histone post-translational modification, HDACs can also post-translationally 
modulate a variety of non-histone proteins, such as transcription factors to regulate a multitude 
of cellular processes (Seto and Yoshida, 2014). Especially class I HDACs were described to 
conduct a critical role in regulation of diverse inflammatory processes by influencing for example 
regulation of Toll-like receptor (TLR) signaling, interferon (IFN)-mediated signaling to modulate 
immune cell proliferation (Kong et al., 2009; Yamaguchi et al., 2010), expression of 
inflammatory mediators (Elsharkawy et al., 2010; Nusinzon and Horvath, 2003; Pakala et al., 
2010) or immune responses against pathogens (Nusinzon and Horvath, 2006; Shakespear et al., 
2011). Additionally, several studies also indicated important class I HDAC functions in vascular 
pathologies, like myocardial infarction or atherosclerosis (Yoon and Eom, 2016; Zampetaki et 
al., 2010) and are therefore of special interest in inflammation-mediated regulation of gene 
expression in endothelial cells. Class I HDACs HDAC1, HDAC2, HDAC3 and HDAC8 are 
ubiquitously expressed enzymes that are mainly located in the nucleus and consist of 
approximately 400 amino acids (de Ruijter et al., 2003; Micelli and Rastelli, 2015). All these 
enzymes share high sequence homology to each other, while HDAC1 and HDAC2 are described 
to be almost identical. The N-terminal catalytic domain of class I HDACs is conserved and 
requires a zinc ion for catalytic activity (de Ruijter et al., 2003; Yang and Seto, 2008), although, 
the detailed catalytic mechanism is still unclear and needs to be investigated (Micelli and Rastelli, 
2015). 
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 Aim of this study 
Gansler et al. found massive downregulation of the protective vascular factor RNase1 upon 
proinflammatory stimulation of human ECs and provided first insights on RNase1 regulation in 
this context. They observed the recovery of RNase1 mRNA expression by pretreatment of 
HUVEC with the universal HDAC inhibitor, Trichostatin A, even upon proinflammatory 
stimulation. Based on these findings, the authors postulated an HDAC-dependent mechanism for 
RNase1 regulation in inflamed ECs (Gansler et al., 2014). HDACs are known as important 
regulators of gene expression by modifying the chromatin structure due to histone deacetylation. 
In this regard, this study aimed to clarify the underlying mechanism of RNase1 suppression during 
vascular inflammation on chromatin level and the impact of HDACs in this process. Specific 
objectives were to identify and localize the RNASE1 promoter region, analyze its acetylation 
status and further investigate the regulatory impact of responsible HDACs for histone 
deacetylation in this region.
Results 
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2 Results 
 Regulation of RNase1 mRNA abundance in inflamed endothelial cells 
To investigate the precise regulation of RNase1 mRNA abundance in inflamed ECs, HUVEC 
were stimulated with proinflammatory cytokines TNF-α and IL-1β [10 ng/ml] over a time course 
of 0.5 to 24 h. mRNA levels of RNase1 as well as the known EC marker E-selectin were 
investigated by quantitative real-time polymerase chain reaction (qRT-PCR). Successful 
stimulation was confirmed by significant increase in E-selectin mRNA expression over time for 
both stimuli (Supplemental Fig. S1A; see page 40) (Edelstein et al., 2005). In comparison, 
RNase1 mRNA abundance was decreased after 6 h of cytokine treatment, and further extended 
to significant downregulation after 9 h and 24 h TNF-α and IL-1β stimulation (Fig. 1A; see page 
30). To investigate whether RNase1 downregulation is generally induced upon proinflammatory 
stimulation or whether this effect seems to be a more precise inflammatory response, HUVEC 
were treated with a subset of proinflammatory stimulants for 24 h, namely IL-13 [50 ng/ml], 
IFN-γ [250 ng/ml], transforming growth factor (TGF)-β [1 µg/ml], polyinosinic polycytidylic 
acid (Poly I:C) [10 µg/ml], lipopolysaccharide (LPS) [100 ng/ml] as well as the trifluoroacetate 
salt Pam3CSK4 [200 ng/ml]. Although with less extend than TNF-α, a significant decrease in 
RNase1 mRNA abundance was only observed upon treatment with the TLR3 ligand Poly I:C 
(Fig. 1B; see page 30). These results suggest, that only certain proinflammatory stimuli severely 
repress RNase1 mRNA production in inflamed human ECs. 
 Inflammation-mediated histone deacetylation of the RNASE1 promoter 
To investigate underlying regulatory mechanisms of RNASE1 gene expression in inflamed ECs, 
Gansler et al. suggested an HDAC-dependent mechanism (Gansler et al., 2014), implying the 
participation of altered histone acetylation at the RNASE1 promoter region. Therefore, in silico 
analysis using Chromatin immunoprecipitation (ChIP)-sequencing data from HUVEC, obtained 
by the University of California, Santa Cruz, (UCSC) genome browser, were performed to localize 
the promoter region of RNASE1. Here, we focused on specific marks that represent a functional 
promoter site. Besides a binding site for the RNA polymerase II (Pol II) subunit 2A (POLR2A), 
the major subunit of the transcription machinery (Cramer et al., 2008; Cramer et al., 2001), the 
active chromatin mark H3K27ac was identified in close proximity to the different RNASE1 
transcript variants, suggesting a potential transcriptional start site (TSS) in this region (Fig. 2A; 
see page 31). To further examine whether the aforementioned regions also possess promoter 
activity, our cooperation partners from the Department of Biochemistry at the Faculty of Medicine 
at Justus-Liebig-University Giessen generated different RNASE1 promoter constructs (C1-C4) 
and analyzed them for their potential to actively induce transcription by luciferase reporter assay 
(Fig. 2B; see page 31). Thereby, the obtained results indicated transcriptional activity of the 
RNASE1 gene regions amplified by construct C2 and C3. Interestingly, both regions harbor not 
only a binding site for the Pol II transcription machinery and the active chromatin mark H3K27ac 
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but also the potential TSS of RNASE1 (Fig. 2A). In addition to the transcriptionally active part of 
promoters (TSS), whole promoter regions are described to be very large and usually divided into 
three parts (Wang et al., 2009): the core promoter, which is known to be located approximately 
100 bp around the TSS, designated as region A for RNASE1, and the proximal and distal promoter 
that are located approximately 500 bp and 1000 bp upstream of the TSS, respectively, designated 
as region B and region C of the RNASE1 promoter region (Fig. 2A). Therefore, region A-C of the 
predicted RNASE1 promoter were included in the following investigations. 
Since chromatin modifications in promoter regions highly influence accessibility of the 
transcription machinery to the DNA, the composition of histone PTMs at promoter sites is 
significantly involved in the regulation of gene expression (Bannister and Kouzarides, 2011; 
Grewal and Elgin, 2007). Here, we investigated the influence of the proinflammatory cytokines 
TNF-α and IL-1β on chromatin modifications of the predicted RNASE1 promoter regions. To 
determine the accessibility of the transcription machinery to chromatin, Pol II recruitment as well 
as the active histone modifications, H4ac and H3K27ac, were examined in region A-C of the 
RNASE1 promoter by ChIP. HUVEC were treated for 30 min with TNF-α or 60 min with IL-1β 
and successful experimental settings were validated by recruitment of Pol II as well as H4ac and 
H3K27ac at the promoter region of E-SELECTIN (PrE-SELECTIN). E-SELECTIN expression is 
known to be upregulated upon proinflammatory stimulation in HUVEC, accompanied by 
increased Pol II recruitment and histone acetylation (Edelstein et al., 2005). Consisting with these 
data, our results revealed an increase in Pol II recruitment as well as H4ac and H3K27ac at 
PrE-SELECTIN upon TNF-α and IL-1β treatment (Supplemental Fig. S1C; see page 40). In case of 
RNASE1, increased Pol II recruitment and significantly elevated H4ac and H3K27ac were 
determined in control cells (Fig. 3; see page 32), predominantly at the TSS (region A), while 
impaired accessibility of Pol II recruitment to region A goes along with significant reduction in 
H4Ac and H3K27ac upon proinflammatory stimulation (Fig. 3A). Similar effects were obtained 
by analysis of region B (Fig. 3B) and region C (Fig. 3C), although to a lesser extent. Here, Pol II 
recruitment was almost absent in control as well as stimulated cells, while only slight reductions 
of H4ac and H3K27ac were obtained upon proinflammatory stimulation compared to control 
cells. In conclusion, proinflammatory stimulation of HUVEC mediated reduction of Pol II 
recruitment and the active chromatin marks, H4ac and H3K27ac, at the core promoter of RNASE1 
(region A), implicating their potential role in inflammation-mediated downregulation of RNase1.  
 Class I HDACs are responsible for TNF-α-mediated RNase1 repression 
Our data nicely demonstrated the importance of H4ac and H3K27ac on RNASE1 expression and 
is consistent with previous results, suggesting participation of HDACs in RNase1 regulation 
(Gansler et al., 2014). To further identify, which distinct HDACs are responsible for RNase1 
regulation in ECs, the endothelial cell line EA.hy926 and HUVEC were treated with different 
HDAC inhibitors prior to 24 h cytokine stimulation. Therefore, the HDAC6 specific inhibitor 
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Tubacin (Haggarty et al., 2003a; Haggarty et al., 2003b) and the class I HDAC inhibitor MS275, 
which specifically targets HDAC1-3 (Kalin et al., 2018; Leus et al., 2017) were tested, while 
DMSO served as solvent control. In Tubacin treated EA.hy926, almost no regulation of RNase1 
mRNA was observed in control as well as TNF-α treated cells, compared to the solvent control 
(Fig. 4A, left panel; see page 33). By contrast, MS275 treatment slightly increases RNase1 mRNA 
abundance in EA.hy926 and HUVEC under physiological conditions. Interestingly, cytokine 
stimulation significantly decreased RNase1 mRNA in DMSO treated cells, while MS275 
treatment completely rescued RNase1 mRNA expression (Fig. 4A, right panels). These results 
indicated a prominent role of the class I HDACs HDAC1-3 in regulation of RNase1. 
To further validate the impact of HDAC1-3 on RNASE1 promoter acetylation, HUVEC treated 
with MS275 prior to TNF-α stimulation were used for ChIP analyses (Fig. 4B-C; see page 33). 
Successful stimulation was validated by investigation of PrE-SELECTIN (Supplemental Fig. S1D; see 
page 40). Here, cytokine stimulation increases Pol II recruitment to PrE-SELECTIN and histone 
acetylation of H4 and H3K27 was significantly elevated compared to controls, both in DMSO as 
well as MS275 treated cells. In comparison, analyses of the RNASE1 core promoter region A in 
DMSO treated cells revealed a significant decrease in Pol II recruitment, H4ac, and H3K27ac 
upon TNF-α stimulation. These effects were abolished by MS275 treatment resulting in recovery 
of Pol II recruitment, H4 and H3K27 acetylation of region A even upon TNF-α treatment 
(Fig. 4B). Although no significant changes were detected for Pol II binding in the more upstream 
regions of the TSS, region B and region C, comparable results were obtained for H4ac and 
H3K27ac. Hence, TNF-α stimulation induced significant deacetylation of H4 and H3K27 in 
DMSO treated cells, but the acetylation was restored by MS275 treatment (Fig. 4C, D; see page 
33). Altogether, inhibition of HDAC1-3 function by MS275 restored histone acetylation (H4, 
H3K27) at the RNASE1 promoter region A-C predicting an essential regulatory impact of 
HDAC1-3 on RNASE1 in inflamed ECs.  
 TNF-α treatment promotes HDAC2 recruitment to the RNASE1 promoter 
To examine, which class I HDACs (HDAC1-3) occupy a predominant role in RNASE1 promoter 
deacetylation, recruitment of HDAC1-3 to the RNASE1 promoter was investigated by ChIP 
kinetics. Therefore, HUVEC were treated for 5-30 min with TNF-α and accumulation of 
HDAC1-3 to RNASE1 region A-C was investigated in comparison to control cells. Initially, 
significantly increased Pol II recruitment to PrE-SELECTIN over time validated successful stimulation 
(Supplemental Fig. S2A; see page 42). In respect to RNASE1, a slight increase in Pol II 
recruitment was detected after 10 min of stimulation at region A that was subsequently decreased 
over time, while almost no Pol II was recruited to upstream regions B and C (Supplemental 
Fig. S2B; see page 42). Interestingly, HDAC2 (green line) significantly accumulated after 10 min 
of cytokine stimulation at the RNASE1 core promoter region A, while almost no HDAC1 (blue 
line) and HDAC3 (red line) recruitment was detected in control and TNF-α treated HUVEC. 
Results 
10 
Although HDAC2 accumulation decreased over time, it still exceeded HDAC1 and HDAC3 
levels (Fig. 5A: left panel, qualitative analysis; right panel, quantitative analysis; see page 34). 
Comparable HDAC accumulation was obtained for region B upon TNF-α treatment (Fig. 5B; see 
page 34), while no distinct HDAC recruitment could be observed at region C (Supplemental 
Fig. S2D; see page 42). To exclude that the detected HDAC accumulation at the RNASE1 
promoter was reliant on differential abundance in the cells, mRNA expression of HDAC1-3 was 
analyzed by qRT-PCR in TNF-α as well as IL-1β stimulated HUVEC over time (Supplemental 
Fig. S3; see page 42). Since no significant changes in mRNA expression of all three HDACs were 
detected upon stimulation, HDAC recruitment to the RNASE1 promoter was suggested to be 
independent of HDAC mRNA abundance in the cells. In conclusion, these results demonstrated 
a significant impact of HDAC2 in inflammation-mediated RNASE1 regulation in human ECs 
through its accumulation to the RNASE1 promoter.  
 HDAC2 and HDAC1 redundantly act on RNase1 expression in inflamed 
endothelial cells 
To further verify the specific impact of HDAC2 in RNase1 regulation, small interfering RNA 
(siRNA) knockdown (KD) was performed in the hybrid endothelial cell line EA.hy926. Besides 
HDAC2 single KD, HDAC1 single KD as well as double KD of HDAC1 and HDAC2 was 
conducted, allocable to the known functional redundancy of HDAC1 and HDAC2 and their 
operation in the same co-repressor complexes (Sengupta and Seto, 2004; Yang and Seto, 2008). 
KD efficiency was validated by quantitative mRNA analysis of HDAC1 and HDAC2 in control 
and TNF-α treated cells, resulting in significant downregulation of the respective mRNAs upon 
siRNA treatment (Fig. 6A; see page 35). To clearly point out the impact of HDAC1 and HDAC2 
siRNA KD on RNase1 mRNA abundance, results were depicted as fold-change values 
normalized to siRNA control in unstimulated cells (Fig. 6B, left panel; see page 35) as well as 
relative percentages of mRNA abundance in TNF-α treated cells, normalized to the respective 
KD in untreated cells (Fig. 6B, right panel). Thus, cytokine stimulation of EA.hy926 in siRNA 
control as well as single siRNA KD cells resulted in significant reduction of RNase1 mRNA to 
65-70% of the respective control cells. This effect was only prevented by double KD of HDAC1 
and HDAC2 (Fig. 6B, left panel). In addition, relative RNase1 mRNA expression upon TNF-α 
stimulation was significantly decreased in control and single transfected cells. However, this 
effect could be significantly restored in HDAC1/2 double KD cells compared to siRNA control, 
HDAC2 siRNA and almost significantly to HDAC1 siRNA single KD cells (Fig. 6B, right panel).  
Altogether, HDAC2 was suggested to be the most prominent class I HDAC involved in RNase1 
regulation by its accumulation (Fig. 5) and subsequent deacetylation of the RNASE1 promoter 
(Fig. 4). However, only double KD of HDAC1 and HDAC2 successfully restored RNase1 
abundance in inflamed ECs (Fig. 6), indicating that loss of HDAC2 presumably enables HDAC1 
to regulate RNase1 expression redundantly.   
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3 Discussion 
Cardiovascular pathologies cause nearly 18 million deaths per year worldwide representing 
approximately 31% of all global deaths (WHO, 2017). The development and progression of such 
diseases, e.g. thrombosis, atherosclerosis or myocardial infarction, caused by vascular 
inflammation, infection or injury, are tightly associated to the loss of EC barrier function which 
usually occupies a crucial role in maintenance and integrity of vascular homeostasis (Poredos, 
2002; Sitia et al., 2010; Zernecke and Preissner, 2016). Therefore, investigation of underlying 
mechanisms of EC inflammation and dysfunction is of global interest. Here, we investigated the 
inflammation-mediated regulation of RNase1 in human ECs, a critical regulator of vascular 
integrity and protective factor in cardiovascular pathologies (Gansler et al., 2014; Zernecke and 
Preissner, 2016). We identified the transcriptionally active RNASE1 promoter region via 
luciferase reporter assays and further investigated the chromatin state of the RNASE1 promoter 
with focus on deacetylation and the responsible mediating enzymes, class I HDACs, by ChIP, 
inhibitor treatment and siRNA KD. Finally, we confirmed an HDAC2-dependent mechanism of 
RNASE1 deacetylation upon inflammation of human ECs. 
RNase1 has been discovered as a potent regulator of EC function and protective factor in 
maintenance of vascular homeostasis. In this regard, RNase1 counteracts the function of eRNA 
for balancing the RNase1-eRNA system protecting thereby the vascular homeostasis to prevent 
eRNA-associated progression of vascular pathologies (Figure I). By doing so, RNase1 
administration was shown to improve the outcome of different vascular pathologies, such as 
reduction of thrombus or edema formation by eliminating proinflammatory cytokine expression 
as well as plaque development and supporting beneficial disease outcome of ischemic heart 
disease (Cabrera-Fuentes et al., 2015b; Cabrera-Fuentes et al., 2014; Fischer et al., 2007; 
Kannemeier et al., 2007; Walberer et al., 2009). However, Gansler et al. demonstrated that 
prolonged inflammation of vascular ECs results in impaired RNase1 expression and function. 
Thereby, long-term inflammation induces significant downregulation of RNase1 mRNA and 
increasing eRNA levels in the extracellular space. Followed by a loss of vascular integrity, for 
instance by redistribution of the vascular adhesion molecule vascular endothelial cadherin and 
subsequent increase in vascular permeability. Moreover, it was demonstrated that inflammation-
mediated downregulation of RNase1 can be blocked by addition of the universal HDAC inhibitor 
trichostatin A, suggesting an HDAC dependent regulatory mechanisms of RNase1 on chromatin 
level (Gansler et al., 2014). Consequently, the development of new therapeutic strategies to fight 
cardiovascular diseases presupposes the identification of underlying molecular mechanisms of 
RNase1 regulation in inflamed ECs.  
Here, we demonstrated that the significant downregulation of RNase1 mRNA abundance upon 
TNF-α and IL-1β stimulation increases over a time course of 24 h in primary human vascular ECs 
(Fig. 1A), confirming previous results by Gansler et al. (Gansler et al., 2014). Interestingly, other 
Discussion 
13 
general proinflammatory agents failed to block RNase1 expression with exception of the TLR3 
ligand Poly I:C, a synthetic double-stranded RNA analog that induced comparable 
downregulation of RNase1 after 24 h stimulation (Fig. 1B). Hence, RNase1 downregulation in 
ECs might not be a general proinflammatory reaction but rather a specific inflammatory response 
to only a small subset of stimuli. Based on these findings, a common signaling pathway, activated 
upon TNF-α, IL-1β and Poly I:C treatment, is suggested to be required for RNase1 regulation. 
All three stimuli can mediate the regulation of gene expression by two distinct signaling cascades 
via nuclear factor kappa B (NF-κB) or mitogen activated protein kinases (MAPK) (Brenner et al., 
2015; Kawai and Akira, 2006; Weber et al., 2010). Here, Gansler et al. already confirmed an 
NF-κB-independent mechanism for RNase1 regulation, since the NF-κB inhibitor BAY 11-7082 
did not prevent TNF-α- or IL-1β-mediated RNase1 downregulation (Gansler et al., 2014). Besides 
that, TNF-α, IL-1β and Poly I:C can induce MAPK signaling through activation of p38 MAPK 
or c-Jun N-terminal kinase (JNK) (Brenner et al., 2015; Kawai and Akira, 2006; Weber et al., 
2010). Consequently, it is proposed that signaling via MAPK is responsible for regulation of 
RNase1 in ECs. Therefore, identification of specific signaling pathways will be of future interest 
to offer a broad spectrum of novel potential targets for treatment of RNase1-associated vascular 
dysfunction. Interestingly, although not significant, our data suggested a tendency of 
IFN-γ-mediated RNase1 upregulation (Fig. 1B). The IFN-γ immune response is tightly associated 
to host defense and clearance of viral as well as bacterial infections (Shtrichman and Samuel, 
2001), which is consistent with already described functions of RNase1. Besides its function as 
vessel protective factor, RNase1 is also associated to host defense, for example by its antiviral 
activity against human immunodeficiency virus 1 or its antibacterial activity against 
pneumococcal infections (Lee-Huang et al., 1999; Zakrzewicz et al., 2016). Therefore, it would 
be interesting to further elucidate the role of IFN-γ as an RNase1 promoting factor in 
IFN-γ-mediated antimicrobial immune responses as well as vascular inflammation.  
To investigate the influence of proinflammatory stimulation on the chromatin state of RNASE1 in 
ECs, identification of the RNASE1 promoter region was necessary. In this regard, core promoters 
usually comprises several specific marks for open and therewith actively transcribed chromatin, 
like H3K27ac marks (Creyghton et al., 2010; Karlic et al., 2010; Wang et al., 2009; Wang et al., 
2008), while the proximal and distal promoter regions also contain additional regulatory elements 
(Wang et al., 2009). One major factor to identify actively transcribed promoter sites is the 
chromatin accessibility of the Pol II transcription complex, a crucial factor for successful 
transcription. Thereby, the largest subunit of this complex, POLR2A, is essential for complex 
binding and its catalytic activity (Cramer et al., 2008; Cramer et al., 2001; Wang et al., 2009). 
Based on high-throughput screenings, provided by the UCSC Genome Browser, a binding site for 
POLR2A was predicted directly upstream of the different RNase1 transcript variants (Fig. 2A). 
In addition, further marks for active promoter regions, namely a DNase hypersensitivity site, a 
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CTCF (CCCTC-binding factor) and c-fos (fos protooncogene) transcription factor binding site as 
well as the H3K27ac histone mark (Fig. 2A), were identified in close proximity to this area. 
Additionally, the precise location of the core promoter of RNASE1 was further confirmed by 
significant transcriptional activity of construct C2 and C3 of the RNASE1 gene in luciferase 
reporter assays (Fig. 2B). Altogether, these results support the localization of the potential core 
promoter and TSS in region A of the RNASE1 gene. The suggested transcriptional activity of 
region A was further confirmed by ChIP that revealed increased Pol II recruitment to this region 
under physiological conditions that was subsequently vanished upon proinflammatory stimulation 
(Fig. 3). This loss of Pol II recruitment to the TSS of RNASE1 further corresponds to the decrease 
in RNase1 mRNA expression in inflamed ECs (Fig. 1). Besides Pol II binding, chromatin 
modifications display a crucial role in regulation of gene expression. Thereby, especially the 
acetylation status of promoter regions is of great importance to distinguish between transcriptional 
activity and repression (Figure IIB) (Karlic et al., 2010; Wang et al., 2009; Wang et al., 2008). 
Here, not only the core promoter region A but also the more upstream regions of the proximal and 
distal promoter, depicted as region B and region C, respectively, were investigated in terms of 
active histone marks. Similar to Pol II, H4 and H3K27 acetylation was increased at the RNASE1 
promoter under physiological conditions and significantly deacetylated upon proinflammatory 
stimulation of HUVEC (Fig. 3). These findings are consistent with the literature, which described 
tight relations of chromatin acetylation and active transcription (Shahbazian and Grunstein, 
2007). Thereby, H3K27 as well as H4 acetylation were associated with gene expression and 
especially acetylation of H3K27 located in close proximity to TSS of transcribed genes was 
proposed to prevent repressive effects of trimethylation at the same lysine residue of histone 3 
(Karlic et al., 2010; Wang et al., 2008). Moreover, Roh et al. demonstrated in activated T-cells, 
a tight correlation of chromatin accessibility and gene expression with increased acetylation at 
promoter regions by using high-resolution genome wide mapping strategies (Roh et al., 2005). 
Specifically in ECs, high-throughput analysis of TNF-α treated HUVEC identified increased 
H3K27ac levels as active marker for upregulated gene expression, to correlate gene transcription 
and histone modifications (Li et al., 2012). Vice versa, transcriptional repression was tightly 
associated to histone deacetylation: in HUVEC, the transcription factor BACH1 (BTB domain 
and CNC homolog 1) mediated HDAC1 recruitment to the IL-8 promoter, resulting in repressed 
gene expression due to H3 and H4 deacetylation (Jiang et al., 2015), while HDAC1 also facilitated 
H3 and H4 deacetylation at target gene promoters in NF-κB-mediated angiogenesis of vascular 
ECs (Aurora et al., 2010). Accordingly, RNASE1 promoter deacetylation of H4 and H3K27 
augmented histone-DNA interactions to promote a tightly packed chromatin structure, resulting 
in diminished Pol II binding to the TSS of RNASE1 and subsequent gene repression (Fig. 3). 
Due to significant deacetylation of the RNASE1 promoter in inflamed human ECs, HDAC 
enzymes that mediate histone deacetylation were of great importance for the underlying 
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investigations. Our results demonstrated the particular impact of class I HDACs, HDAC1, 
HDAC2, and HDAC3 in RNASE1 regulation. In this respect, treatment with the 
HDAC1-3-specific inhibitor MS275 successfully restored RNase1 mRNA abundance in TNF-α 
treated HUVEC (Fig. 4A) by recovering not only H4 and H3K27ac in the RNASE1 promoter 
region A-C, but also restoring Pol II recruitment to the RNASE1 TSS in region A (Fig. 4B-D). 
These results are in line with already described experiments were MS275 administration 
successfully enhanced H4 and H3 acetylation in pediatric tumor cell lines or LPS/IFN-γ 
stimulated macrophages (Jaboin et al., 2002; Leus et al., 2017), as well as counteracted 
hypo-acetylation in the immature hippocampus in a rat model system (Joksimovic et al., 2018). 
Therefore, HDAC1-3 are suggested to be crucial regulators in inflammation-mediated RNase1 
repression in human ECs and validation of specific HDAC recruitment to the RNASE1 promoter 
in inflamed ECs was of major interest. Here, we demonstrated that HDAC1 and HDAC3 were 
almost not recruited to the RNASE1 promoter, while HDAC2 significantly accumulated to 
region A and B of RNASE1 upon proinflammatory stimulation (Fig. 5). Accordingly, 
proinflammatory stimulation of human ECs mediates HDAC2 recruitment to the RNASE1 
promoter to enable local histone deacetylation and transcriptional repression. Thereby, indicating 
a significant impact of HDAC2 in RNase1 regulation in inflamed ECs. 
Interestingly, the literature describes the possibility of functional redundancy between HDAC2 
and HDAC1, so we included HDAC1 in the functional characterization of HDAC-mediated 
RNase1 regulation by siRNA KD. Our results revealed that only double KD of HDAC1 and 
HDAC2 significantly prevented RNase1 downregulation upon TNF-α stimulation (Fig. 6). These 
findings indicate functional redundancy of HDAC1 and HDAC2 in RNase1 regulation, where 
HDAC1 is able to partially takeover the RNase1 regulatory function in absence of HDAC2. The 
functional redundancy of HDAC1 and HDAC2 implicates that both enzymes conduct by similar 
molecular mechanisms and is promoted by the high sequence similarity of HDAC1 and HDAC2 
of ~75% and even more identity on protein level. Thus, both enzymes are known to associate and 
function either as homo- or heterodimers in the same multiprotein co-repressor complexes to 
mediate transcriptional repression, namely Sin3 complex, REST co-repressor complex (CoREST) 
and the Nucleosome Remodeling and Deacetylase (NuRD) complex (Sengupta and Seto, 2004; 
Tong et al., 1998; Yang and Seto, 2008; You et al., 2001; Zhang et al., 1997). Moreover, the 
functional redundancy of HDAC1 and HDAC2 has been also described in literature, for instance 
in the context of cardiac morphogenesis or oocyte development in mice as well as B-cell 
development (Ma et al., 2012; Montgomery et al., 2007; Yamaguchi et al., 2010). Nevertheless, 
even double KD of HDAC1 and HDAC2 was not able to obtain a complete recovery of RNase1 
mRNA expression (Fig. 6). Since, HDAC proteins are essential regulators of gene transcription, 
it is hardly surprising that they conduct high protein stability. Thus, these enzymes might still 
exist even after 48 h of siRNA treatment or gene inactivation (Jamaladdin et al., 2014; Kallsen et 
Discussion 
16 
al., 2012; Lee et al., 2014; Mercado et al., 2011), which might explain the still partially regulated 
RNase1 expression.  
Although there is indication for functional redundancy between HDAC1 and HDAC2 in 
inflammation-mediated RNase1 regulation, HDAC2 yet persist as the major regulator, due to its 
significant accumulation at the RNASE1 promoter. The crucial impact of class I HDACs, 
particularly HDAC2, in inflammation supports our current findings. Zhang and colleagues 
described that LPS induced inflammation of myeloid cells resulted in HDAC2-mediated 
deacetylation of H4 and H3 of the IL-6 promoter and subsequent gene repression (Zhang et al., 
2015). Comparable results for HDAC2 function were observed in context of chronic 
inflammatory diseases, such as rheumatoid arthritis or multiple sclerosis. Here, HDAC2 is 
recruited to the IL-17 promoter to mediate its downregulation due to dysregulation of the RORγ 
(RAR-related orphan receptor γ) transcription factor (Singh et al., 2018). Moreover, HDAC2 also 
acts specifically in the context of vascular inflammation, where it influences progression of 
atherogenesis by deacetylation-mediated repression of the transcription factor CIITA (class II 
transactivator) in macrophages and smooth muscle cells (Kong et al., 2009). All these studies 
emphasize the important function of HDAC2 in inflammatory processes, demonstrating the 
requirement to attend inflammatory and vascular disorders by targeting HDAC2 with novel 
therapeutic strategies.  
In this regard, HDAC inhibitors specifically target HDAC function and have already been defined 
as upcoming medical treatments for inflammatory disorders. Thereby, cell survival and 
proliferation in several cancer types has been described to be influenced by highly elevated class I 
HDAC expression, e.g. HDAC2 in cervical or gastric cancer (Huang et al., 2005; Song et al., 
2005). In this context, clinical treatment with universal HDAC inhibitors is already applied for 
diverse cancers such as ovarian cancer or cutaneous T-cell lymphoma. Thereby, robust induction 
of cancer cell differentiation due to histone acetylation was mediated by HDAC inhibition to 
increase susceptibility of these cells to chemotherapeutics (Caslini et al., 2006; Mann et al., 2007; 
Yoon and Eom, 2016). Universal HDAC inhibitors were also validated to improve progression of 
cardiovascular diseases, such as inhibition of fibrosis and cardiac hypertrophy, preserving cardiac 
function after myocardial infarction and ischemia-reperfusion injury, as well as preventing 
progression of atherosclerosis (Eom et al., 2011; Findeisen et al., 2011; Granger et al., 2008; Kee 
et al., 2011; Kee et al., 2006; Kong et al., 2006; Okamoto et al., 2006). Additionally, new 
promising therapies to treat HDAC-related disorders using more specific HDAC inhibitors are 
already under approval in clinical trials, for example MS275 that functions as antiepileptic or 
breast/lung cancer treatment. However, a persistent problem occurred: Even specific HDAC 
inhibitors not only target one distinct HDAC, for instance HDAC2, but rather targeting a distinct 
group of closely related HDACs, such as HDAC1-3 in terms of MS275. This issue is further 
attenuated due to the close relation of HDAC enzymes and their diverse functions and interaction 
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partners in different cellular contexts, making development and generation of HDAC specific 
inhibitors even more challenging (Bantscheff et al., 2011; Falkenberg and Johnstone, 2014; 
Roche and Bertrand, 2016). In addition, functional redundancies between different enzymes, as 
demonstrated for HDAC1 and HDAC2, amplify these problematics (Haberland et al., 2009; 
Jurkin et al., 2011), but there is already ongoing progress in the development of enzyme-specific 
HDAC inhibitors or specifically interfering with HDAC functions at different cellular levels, for 
example by inhibition of interaction partners (Wagner et al., 2015; Yamakawa et al., 2017).  
Irrespective of the described issues, this study revealed a protective function of MS275 in 
recovery of the essential vascular factor RNase1 during inflammation of human ECs. In 
combination with the vessel-protective role of RNase1 in vascular pathologies, like reduction of 
myocardial infarction size in a rat model system or protecting the heart against 
ischemia-reperfusion injury (Cabrera-Fuentes et al., 2015b; Lu et al., 2018; Simsekyilmaz et al., 
2014), the observed function of MS275 offers new therapeutic strategies to fight cardiovascular 
disorders. 
Concerning the transfer of these results to a clinical setting, certain limitations have to be 
considered: The presented study is based on in vitro experiments. Cultured EC monolayers are 
widely used to investigate diverse scientific objectives of EC function and dysfunction. However, 
selection of an accurate EC model system is essential, since ECs from different origins might 
behave differently (Kvietys and Granger, 1997). In this regard, we used HUVEC as primary 
human EC model. HUVEC express and secrete high amounts of RNase1 (Fischer et al., 2011; 
Landre et al., 2002) and are the most often used EC model for investigation of inflammatory 
issues in humans (Bouis et al., 2001; Kvietys and Granger, 1997). Additionally, compared to 
other primary tissue, human umbilical cords are more easily accessible and HUVEC can be 
isolated with a relatively high yield of cell number and purity (Jaffe et al., 1973; Kvietys and 
Granger, 1997). However, HUVEC can be used only in low passages to preserve their primary 
EC character, comprise a high donor variancy (Bouis et al., 2001) and HDAC siRNA transfection 
turned out to induce unintended side effects in this study. In this regard, alternative methods to 
obtain HDAC-specific depletion in HUVEC could be suggested, e.g. lentiviral transduction, 
which was already successfully performed in these cells (Margariti et al., 2010). Due to these 
limitations, additionally the human hybrid EC cell line EA.hy926 was included in our studies, as 
they enable siRNA transfections and express and secrete decisive amounts of RNase1 (Landre et 
al., 2002). Despite their hybrid origin (a fusion of HUVEC and the cancerogenic epithelial cell 
line A549), EA.hy926 are generally used as human vascular EC line model due to its 
well-characterized endothelial phenotype (Bouis et al., 2001). Nevertheless, in vitro EC 
monolayers differ from an intact endothelium and validation of the presented data in in vivo 
studies will be of future interest. Here, the demonstrated protective function of MS275 on RNase1 
has to be investigated in context of cardiovascular pathologies. Additionally, siRNA KD of 
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HDACs appeared to be difficult due to their global function and high protein stability. Thus, the 
impact of HDAC2 on RNase1 in a cardiovascular disease model in EC-specific HDAC2 knockout 
mice can be suggested, since HDAC2-null mice appeared to be lethal (Montgomery et al., 2007). 
Summary and Outlook 
Altogether, the data presented here proposes the following mechanistic model of RNase1 
regulation in human ECs (Figure III): Under physiological conditions, the RNASE1 promoter 
region (region A-C) is acetylated at H4 and H3K27, resulting in a relaxed and open chromatin 
structure. This structure provides access of the Pol II transcription machinery to the DNA and 
promotes RNASE1 expression (Figure IIIA). In comparison, proinflammatory stimulation, for 
instance by TNF-α, IL-1β or Poly I:C, induces HDAC2 recruitment to the RNASE1 promoter by 
a so far unidentified co-repressor complex. Hence, HDAC2 mediates deacetylation of H4 and 
H3K27 at the RNASE1 promoter to support a tightly packed, inactive chromatin structure. 
Consequently, binding of the Pol II transcription machinery to the RNASE1 TSS and subsequent 
RNASE1 expression is suppressed (Figure IIIB).  
 
Figure III: HDAC2-mediated deacetylation of the RNASE1 promoter. Model of RNASE1 promoter 
acetylation state in human endothelial cells under A) physiological and B) proinflammatory conditions. A) 
Under physiological conditions, RNASE1 promoter acetylation at histone 4 and histone 3 lysine 27 in region 
A-C supports an open chromatin structure, RNA Polymerase II (Pol II) transcription machinery binding and 
RNASE1 expression. B) Proinflammatory stimulation induces deacetylation of RNASE1 promoter region 
A-C through co-repressor complex-mediated HDAC2 recruitment, resulting in a condensed chromatin 
structure, loss of Pol II binding and RNASE1 repression. Abbreviations: Ac, acetylation; bp, base pairs; 
HDAC2, histone deacetylase 2; Pol II, RNA polymerase II; RNASE1, Ribonuclease 1 gene; TSS, 
transcriptional start site; up., upstream.  
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This study partially describes the underlying molecular mechanism of HDAC2-mediated RNase1 
regulation in inflamed human ECs. Nevertheless, many aspects of this mechanism remain 
unknown and need to be investigated in future studies: First, the involved signaling pathways 
from EC stimulation to RNASE1 promoter deacetylation are still obscure and should be of future 
interest. Our data suggested a common signaling mechanism for RNase1 regulation via MAPK 
p38 and JNK (Brenner et al., 2015; Kawai and Akira, 2006; Weber et al., 2010). Therefore, it 
would be interesting to elucidate the participation of these signaling pathways in RNase1 
regulation. Besides that, the analysis of IFN-γ-mediated signaling and its function as a potential 
novel RNase1 protective factor should be further investigated. Second, apart from signaling 
pathways, it is still unclear how HDAC2 is activated and recruited to the RNASE1 promoter in 
our model. In this respect, no changes in mRNA abundance upon proinflammatory stimulation 
were detected for HDAC2 over HDAC1 and HDAC3. This indicates that specific accumulation 
of HDAC2 to the RNASE1 promoter might depend on changes in its protein abundance or 
function. According to literature, activity and complex formation of HDAC2 is regulated through 
PTMs, especially phosphorylation of serine residues that are mediated by the protein kinase casein 
kinase 2 (CK2) (Brandl et al., 2009; Tsai and Seto, 2002). Therefore, it would be interesting to 
investigate, whether CK2 is responsible for RNase1 regulation through modulation of HDAC2 
phosphorylation in EC inflammation. Thirdly, the recruitment of HDAC2 to the RNASE1 
promoter region needs to be investigated. HDACs themselves do not comprise any DNA-binding 
ability and require the function of co-repressor complexes to successfully mediate histone 
deacetylation (Sengupta and Seto, 2004). Thus, it would be necessary to investigate, which 
co-repressor complex, Sin3, CoREST or NuRD (Tong et al., 1998; You et al., 2001; Zhang et al., 
1997), associates with HDAC2 upon EC inflammation to promote its recruitment to the RNASE1 
promoter for subsequent gene repression. Additionally, identification of a specific co-repressor 
complex can further provide information about HDAC2-associated proteins, such as 
DNA-binding proteins, transcription factors, or other complex components essential for RNase1 
regulation. 
Altogether, further investigations are required to unravel the underlying molecular mechanisms 
of proinflammatory regulation of the vessel-protective factor RNase1 in ECs. Thereby, leading to 
the identification of new potential targets, such as signaling pathway components or HDAC2 
interaction partners, to develop novel therapeutic strategies to fight cardiovascular pathologies by 
protecting RNase1 to preserve the vascular integrity.  
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